TG Therapeutics, Inc. (FRA:NKB2)

Market Cap	3.66B -19.8%
Revenue (ttm)	453.34M +100.9%
Net Income	381.38M
EPS	2.37
Shares Out	n/a
PE Ratio	9.61
Forward PE	18.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	24.78
Previous Close	24.49
Day's Range	24.78 - 24.78
52-Week Range	22.47 - 39.98
Beta	n/a
RSI	50.58
Earnings Date	Feb 27, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 374
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NKB2

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD